Nymox Pharmaceutical Corporation news

   Watch this stock
Showing stories 1 - 10 of about 91   

Articles published

NYMX 2.41 -0.01 (-0.41%)
price chart
Here's Why Nymox Pharmaceutical Corporation (NYMX) Stock Gained More Than 100%
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced the results of its long-term extension prospective, double-blind pivotal Phase 3 research today.
Nymox Pharmaceutical Corporation (NYMX) Jumps On News Of Study Results  Insider Monkey (blog)
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Short Interest Update  Money Flow Index
Company Shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Rally 5.83%
Shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) rose by 5.83% in the past week and 86.77% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 5.13% and the outperformance increases to 89.9% for the last 4 ...
Company Shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Rally 2.31%
Shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) appreciated by 2.31% during the past week but lost 16.29% on a 4-week basis.
Shrinking Short Interest in 3 NASDAQ Stocks: Interactive Brokers Group ...  Wall Street Observer
Nymox Pharmaceutical Short Interest Down 33.0% in August (NYMX)
Nymox Pharmaceutical Corporation is a Canada-based biopharmaceutical company. The Company focuses on developing NX-1207, a treatment for benign prostatic hyperplasia (NASDAQ:NYMX) which is in Phase III trials in the United States.
Friday Morning Thoughts: Nymox Pharmaceutical Corporation (NYMX), Conatus ...  WallStreet Scope
Class Action Lawsuit Filed Against Nymox Pharmaceutical Corporation and Paul ...
PHILADELPHIA, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Law Offices Bernard M. Gross, P.C. filed a class action lawsuit in the United States District Court, District of New Jersey, 14-cv-07331, on behalf of purchasers of NYMOX common stock between January ...
Related articles »  
Company Shares of Nymox Pharmaceutical Corporation Rally 107.87%
Shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) rose by 107.87% in the past week and 98.5% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 105.48% and the outperformance increases to 95.94% for the ...
Most Volatile Stocks: SunEdison, Inc. (SUNE), Nymox Pharmaceutical ...  WallStreet Scope
Nymox Pharmaceutical Sees Large Decline in Short Interest (NYMX)
Nymox Pharmaceutical Corporation is a Canada-based biopharmaceutical company. The Company focuses on developing NX-1207, a treatment for benign prostatic hyperplasia (NASDAQ:NYMX) which is in Phase III trials in the United States.
Shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Drops by -14.96%
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) has dropped 14.96% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 70.08% in the last 4 weeks.
Is Nymox a Fluke or Is It Back?
Nymox Pharmaceutical Corp. (NASDAQ: NYMX) has been around for a long time, but within the past five years the stock has literally fallen off a cliff.
Here's Why Nymox Nosedived Yesterday
Nymox Pharmaceutical Corporation (NYMX) was one of the biggest losers in the biotech sector yesterday, as its stock plunged almost 82% on news that the company's key drug candidate was unsuccessful in two late-stage trials.
Nymox Pharma (NYMX) Phase 3 Studies of NX-1207 Fail to Meet Primary Endpoints  StreetInsider.com (subscription)
Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 Fail ...  GlobeNewswire (press release)
Related articles »